TAS-106 is a new nucleoside antimetabolite. TAS-106 has demonstrated strong antitumor activity without serious toxicity in nude rat models bearing human tumours .
- Mechanism
- Curator reviewed
3'-C-ethynylcytidine is metabolized in tumor cells to ethynylcytidine triphosphate (ECTP), which inhibits RNA synthesis by competitive inhibition of RNA polymerases I, II and III; subsequently, RNase L is activated, resulting in apoptosis. RNase L is a potent antiviral and antiproliferative endoribonuclease that cleaves singled stranded RNA, causes 28s rRNA fragmentation, and activates Janus Kinase (JAK), a mitochondrial-dependent apoptosis signaling molecule.
- Primary indication
- Investigated for use/treatment in solid tumors and cancer/tumors (unspecified).Curator reviewed
- Formula / weight
- C11H13N3O5 · 267.241 g/mol (avg)
- Also known as
- 3'-C-Ethynylcytidine
- Code names
- TAS-106
Resolves to
JFIWEPHGRUDAJN-DYUFWOLASA-NSMILESNC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@](O)(C#C)[C@H]1OWhat you can answer from here — as of June 15, 2026
Which drugs share a target with TAS-106, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account